Citadel Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Citadel Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-15,700	Closed	-$282K	–	9187
2017 Q4	$282K	Buy	15,700 +2,600	+20%	+$32K	﹤0.01%	6565
2017 Q3	$155K	Buy	+13,100	New	+$147K	﹤0.01%	6837
2016 Q3	–	Sell	-12,300	Closed	-$135K	–	8120
2016 Q2	$135K	Sell	12,300 -2,800	-19%	-$31.3K	﹤0.01%	6064
2016 Q1	$165K	Buy	15,100 +7,700	+104%	+$97.3K	﹤0.01%	5772
2015 Q4	$128K	Buy	7,400 +2,400	+48%	+$43K	﹤0.01%	6410
2015 Q3	$99K	Buy	+5,000	New	+$115K	﹤0.01%	6969
2015 Q2	–	Sell	-5,100	Closed	-$79K	–	9321
2015 Q1	$79K	Buy	+5,100	New	+$79.1K	﹤0.01%	7044

Other funds holding SCMP

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Citadel Advisors's SCMP Position: Q1 2017 in Review

Citadel Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2017, closing a stake of 61,524 shares — an estimated $834K sold.

Citadel Advisors first reported a position in SCMP in Q2 2013 and held it in 12 quarters. The position peaked at $1.44M in Q1 2015. 167 funds tracked by Wall St. Rank hold SCMP as of Q1 2017.

Citadel Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Citadel Advisors sold 61,524 Sucampo Pharmaceuticals, Inc. shares in Q1 2017, an estimated $834K.
Citadel Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 12 quarters.
Citadel Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $1.44M in Q1 2015.
167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2017.

Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.